APA (7th ed.) Citation

Y, C., J, L., J, C., E, K., Z, L., W, C., & J, L. (2022). The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study. Frontiers in pharmacology, 12, 811700. https://doi.org/10.3389/fphar.2021.811700

Chicago Style (17th ed.) Citation

Y, Chen, Luo J, Chen J, Kotlyar E, Li Z, Chen W, and Li J. "The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study." Frontiers in Pharmacology 12 (2022): 811700. https://doi.org/10.3389/fphar.2021.811700.

MLA (9th ed.) Citation

Y, Chen, et al. "The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study." Frontiers in Pharmacology, vol. 12, 2022, p. 811700, https://doi.org/10.3389/fphar.2021.811700.